Video Experimental Relacionado

Updated: Jul 13, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

FK 506: ¿un inmunosupresor para la década de 1990?

A M Macleod¹, A W Thomson

¹Department of Medicine and Therapeutics, University of Aberdeen Medical School, UK.

Lancet (London, England)

|January 5, 1991

Resumen

El nuevo inmunosupresor FK 506, un potente agente anti-células T, se muestra prometedor en pacientes con trasplante de hígado. Los ensayos clínicos sugieren que FK 506 ofrece un mejor perfil de riesgo / beneficio en comparación con la ciclosporina.

Área de la Ciencia:

Inmunología Inmunología.
Farmacología Farmacología.
Medicina del trasplante Medicina del trasplante.

Sus antecedentes:

FK 506 es un nuevo fármaco macrólido inmunosupresor.
Funciona como un potente y selectivo agente anti-células T.
Su mecanismo de acción es comparable al de la ciclosporina.

Objetivo del estudio:

Evaluar la eficacia y seguridad de FK 506 en receptores de injerto de hígado.
Para comparar la relación riesgo/beneficio de FK 506 frente a la ciclosporina.
Para facilitar una evaluación clínica más amplia de FK 506 en varios entornos de trasplante.

Principales métodos:

Se llevaron a cabo estudios clínicos en receptores de injerto de hígado.
Se realizó un análisis comparativo con ciclosporina.
Actualmente se están llevando a cabo ensayos multicéntricos, prospectivos y controlados en Europa y América del Norte.

Principales resultados:

Los estudios clínicos en receptores de trasplante de hígado demostraron una relación riesgo / beneficio favorable para FK 506 en comparación con la ciclosporina.
FK 506 exhibe una inhibición potente y selectiva de las células T.
Los ensayos en curso están expandiendo la evaluación de FK 506 a través de múltiples tipos de trasplante.

Conclusiones:

FK 506 representa un avance significativo en la terapia inmunosupresora para el trasplante de órganos.
El medicamento muestra potencial para mejorar los resultados de los pacientes en el trasplante de hígado.
Otros ensayos clínicos extensos son esenciales para confirmar su eficacia y seguridad en diversas poblaciones de trasplantes.

Más Videos Relacionados

Forward Genetics Screens Using Macrophages to Identify Toxoplasma gondii Genes Important for Resistance to IFN-γ-Dependent Cell Autonomous Immunity

Forward Genetics Screens Using Macrophages to Identify Toxoplasma gondii Genes Important for Resistance to IFN-γ-Dependent Cell Autonomous Immunity

Published on: March 12, 2015

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Videos de Conceptos Relacionados

Inhibitors of Bacterial Protein Synthesis

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Inhibitors Of Virion Release

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Antifungal Agents

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...